1B and C). But at 0.5 h after LPS administration, sTNF-R1 levels in the LPS + Cap group were significantly

decreased, compared to the LPS group (P < 0.05, Fig. 1B). At 9 h and 12 h after LPS administration, sTNF-R2 levels in the LPS + Cap group were significantly decreased compared to the LPS group (P < 0.01, Fig. 1 C). Compared to the vehicle group, no significant change was observed in the circulating TNF-α, TNF-R1, or TNF-R2 mRNA expression selleck products levels in the Cap group (data not shown). The circulating TNF-α mRNA expression level in the LPS group was significantly increased 0.5, 1, 3, 6, and 9 h after LPS administration (P < 0.05, Fig. 2A) compared to the vehicle group. Despite this, the circulating TNF-α mRNA expression level in the LPS + Cap group significantly decreased 0.5, 1, 3, and 9 h after LPS administration compared to the vehicle group (P < 0.05, Fig. 2A). The circulating TNF-R1 mRNA expression level in the LPS group significantly decreased 0.5, 1, and 3 h after LPS administration compared to the vehicle group (P < 0.05 or 0.01, Fig. 2B), even though they were significantly increased 6 h and 9 h after LPS administration compared to the vehicle group (P < 0.05, Fig. 2B). Furthermore,

the circulating TNF-R1 mRNA expression level in the LPS + Cap group significantly increased 9 h after LPS administration Vorinostat supplier compared with the vehicle group (P < 0.05, Fig. 2B). The circulating TNF-R2 mRNA expression

level in the LPS group significantly decreased 0.5 h after LPS administration compared to the vehicle group (P < 0.05, Fig. 2 C). Despite this, the circulating TNF-R2 mRNA expression level in the LPS + Cap group significantly increased 6 h after LPS administration compared to the vehicle group (P < 0.01, Fig. 2 C). Cap has been previously reported Metalloexopeptidase to improve the survival rate of LPS-treated mice [27], although the precise mechanism of the effect of Cap was not explained. The aim of this study was to elucidate the effect of Cap on circulating biomarkers, sTNF, sTNF-R1, and -R2 levels in LPS-treated mice. Increased circulating sTNF-R1 and -R2 levels have been reported in patients with hepatitis C virus infection [14], and increased circulating sTNF-R2 levels in patients with congestive heart failure [8], obesity-impaired glucose tolerance [7], and leukemia [22] and [26]. In this study, we confirmed that the circulating sTNF-R2 levels in plasma were approximately 10-fold higher than the circulating sTNF-R1 levels at each time point [11]. Since the circulating sTNF, sTNF-R1, and -R2 levels are the initial signals of an immune response, plasma changes in them could represent a biomarker detectable at an earlier stage than C-reactive proteins, leukocytes, and fever during sepsis or systemic inflammatory response syndrome (SIRS). These values thus are known biomarkers of septic shock [2].